How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/prevention-of-respiratory-syncytial-virus-rsv-lower-respiratory-tract-disease.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Prevention of respiratory Syncytial Virus (RSV) lower respiratory tract disease — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prevention of respiratory Syncytial Virus (RSV) lower respiratory tract disease (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Prevention of respiratory Syncytial Virus (RSV) lower respiratory tract disease, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Beyfortus	NIRSEVIMAB	AstraZeneca	Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody [EPC]	RSV	2023-01-01
Beyfortus	Beyfortus	National Institute of Allergy and Infectious Diseases (NIAID)		Fusion glycoprotein F0
BEYFORTUS	NIRSEVIMAB-ALIP	ASTRAZENECA AB	Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody [EPC]	Fusion glycoprotein F0

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

ASTRAZENECA AB · 1 drug in Prevention of respiratory Syncytial Virus (RSV) lower respiratory tract disease
AstraZeneca · 1 drug in Prevention of respiratory Syncytial Virus (RSV) lower respiratory tract disease
National Institute of Allergy and Infectious Diseases (NIAID) · 1 drug in Prevention of respiratory Syncytial Virus (RSV) lower respiratory tract disease

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Prevention of respiratory Syncytial Virus (RSV) lower respiratory tract disease:

Cite this brief

Drug Landscape (2026). Prevention of respiratory Syncytial Virus (RSV) lower respiratory tract disease — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/prevention-of-respiratory-syncytial-virus-rsv-lower-respiratory-tract-disease. Accessed 2026-06-10.

Prevention of respiratory Syncytial Virus (RSV) lower respiratory tract disease full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing